Literature DB >> 2797718

Topical cyclosporine in high-risk corneal transplants.

M W Belin1, C S Bouchard, S Frantz, J Chmielinska.   

Abstract

Cyclosporine (cyclosporin A, CsA) is a selective T-cell immunosuppressant that works primarily through inhibition of both antigen presentation and lymphokine production. It has dramatically improved the prognosis for solid organ transplantation. Significant nephrotoxicity has been associated with its systemic use. Topical CsA 2% was used in 11 high-risk corneal transplant patients (8 men; 3 women; average age, 44 years). Ten (91%) of 11 corneas remained clear at an average follow-up of 16 months (range, 6-24 months). All patients had transient epithelial keratitis. Systemic whole blood levels of CsA measured by high-performance liquid chromatography (HPLC) ranged from 14 to 64 ng/ml. All previous reports on the use of topical CsA in high-risk corneal transplant patients have not detected systemic CsA levels.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2797718     DOI: 10.1016/s0161-6420(89)32756-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  15 in total

Review 1.  Experimental corneal allograft rejection.

Authors:  Bryan M Gebhardt; Weiyun Shi
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Immunology of corneal transplantation.

Authors:  W H Constad; K Taraschanskiy
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

3.  Laser photocoagulation for corneal stromal vascularization.

Authors:  V S Nirankari
Journal:  Trans Am Ophthalmol Soc       Date:  1992

Review 4.  Adult keratoplasty: has the prognosis improved in the last 25 years?

Authors:  Francis W Price; Marianne O Price
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

5.  Update on the Management of High-Risk Penetrating Keratoplasty.

Authors:  Sayena Jabbehdari; Alireza Baradaran Rafii; Ghasem Yazdanpanah; Pedram Hamrah; Edward J Holland; Ali R Djalilian
Journal:  Curr Ophthalmol Rep       Date:  2017-02-02

Review 6.  Literature review and suggested protocol for prevention and treatment of corneal graft rejection.

Authors:  Otavio Azevedo Magalhaes; Ahmed Shalaby Bardan; Mehran Zarei-Ghanavati; Christopher Liu
Journal:  Eye (Lond)       Date:  2019-07-22       Impact factor: 3.775

Review 7.  Management of high-risk corneal transplantation.

Authors:  Antonio Di Zazzo; Ahmad Kheirkhah; Tulio B Abud; Sunali Goyal; Reza Dana
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

8.  Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study.

Authors:  A C Poon; J E Forbes; J K Dart; S Subramaniam; C Bunce; P Madison; L A Ficker; S J Tuft; D S Gartry; R J Buckley
Journal:  Br J Ophthalmol       Date:  2001-12       Impact factor: 4.638

9.  Influence of topical cyclosporine A and dissolvent on corneal epithelium permeability of fluorescein.

Authors:  J M Benítez del Castillo; A Castillo; N Toledano; S Durán; C del Aguila; M Otero; J García-Sanchez
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

Review 10.  Therapeutic options in ocular allergic disease.

Authors:  M Hingorani; S Lightman
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.